AtaiBeckley NV reports encouraging Phase 2a data for EMP-01 in social anxiety

AtaiBeckley NV CEO Dr Srinivas Rao joined Steve Darling from Proactive to discuss topline results from the company’s exploratory, double-blind, placebo-controlled Phase 2a trial evaluating EMP-01 in adults with Social Anxiety Disorder (SAD). The first-in-patient study met its primary safety objective and delivered encouraging secondary and exploratory efficacy signals in what management described as a highly severe, difficult-to-treat patient population. Regarding safety, Rao said EMP-01 demonstrated a favorable and manageable tolerability profile. No serious adverse events were reported, and there were no cases of treatment-emergent suicidal behavior or intent. Most adverse events were mild to moderate in nature and resolved without medical intervention. On efficacy measures, EMP-01 produced a numerically greater reduction in symptoms than placebo as measured by the Liebowitz Social Anxiety Scale (LSAS). At Day 43, the least squares mean reduction from baseline was -28.53 points for EMP-01 compared to -16.67 points for placebo. While the study was not powered for statistical significance, the placebo-adjusted reduction of 11.85 points (Hedges’ g = 0.45; one-tailed p-value = 0.036) is consistent with a moderate treatment effect size and suggests clinically meaningful improvement. Importantly, symptom reductions observed at the six-week endpoint—after just two doses of EMP-01—were comparable in magnitude, in cross-trial comparisons, to improvements typically reported after 8 to 12 weeks of daily SSRI or SNRI therapy in registration studies. On the Clinical Global Impression-Improvement (CGI-I) scale, 49% of patients treated with EMP-01 were rated as “very much improved” or “much improved,” compared to 15% in the placebo group. This 34-percentage-point difference corresponds to a Number Needed to Treat (NNT) of 2.95 (95% CI: 1.84–7.42), indicating a meaningful level of global clinical improvement. Rao noted that more detailed analyses will be presented at upcoming scientific meetings and will inform the next stages of EMP-01’s clinical development program. #proactiveinvestors #ataibeckley #nasdaq #atai #clinicaltrial #bpl003 #depression #EMP01 #SocialAnxietyDisorder #SAD #ClinicalTrials #Phase2a #BiotechNews #DrugDevelopment #MentalHealthInnovation #CNSResearch #Neuroscience #PharmaPipeline #ClinicalResearch #LiebowitzScale #CGII #TreatmentInnovation #HealthcareInvesting #EmergingTherapies #BiotechInvestors